Medicine and Dentistry
Abiraterone
15%
Androgen Receptor
15%
Arm
9%
Biological Marker
26%
Cancer
12%
Castration Resistant Prostate Cancer
31%
Chemoradiotherapy
14%
Clinical Trial
14%
Colorectal Cancer
17%
Disease
21%
DNA Mismatch Repair
12%
DNA Repair
9%
Dysplasia
9%
Enzalutamide
26%
Fluorodeoxyglucose F 18
15%
Gene Mutation
10%
Gleason Score
9%
Hazard Ratio
13%
Head and Neck Cancer
17%
Head and Neck Squamous Cell Carcinoma
20%
Homologous Recombination
8%
Immune Response
9%
Immunotherapy
19%
Ipilimumab
10%
Malignant Neoplasm
18%
Metastatic Carcinoma
16%
Neoplasm
100%
Nivolumab
13%
Nodular Melanoma
16%
Non Small Cell Lung Cancer
9%
Overall Survival
46%
Pancreas Adenocarcinoma
34%
Pancreas Cancer
19%
Phase II Trials
10%
Positron Emission Tomography
14%
Positron Emission Tomography-Computed Tomography
18%
Programmed Death 1 Ligand 1
12%
Programmed Death-Ligand 1
17%
Progression Free Survival
30%
Promoter Region
8%
Prostate Cancer
73%
Prostate Specific Antigen
22%
Prostatectomy
18%
Radiation Therapy
25%
Recurrent Disease
10%
Surgery
15%
T Cell
16%
Treatment Response
9%
Tumor Cell
11%
Wart Virus
11%
Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone
25%
Alkaline Phosphatase
5%
Androgen
44%
Androgen Receptor
21%
Biological Marker
18%
Capecitabine
9%
Castration Resistant Prostate Cancer
53%
CD8 Antigen
11%
Cetuximab
7%
Chemoradiation Therapy
14%
Chemotherapy
14%
Cisplatin
5%
Clinical Study
6%
Clinical Trial
17%
Colorectal Cancer
6%
Disease
16%
Docetaxel
8%
Enzalutamide
38%
Epidermal Growth Factor Receptor
6%
Fluorodeoxyglucose F 18
10%
Fox
5%
Gemcitabine
6%
Gleason Score
9%
Head and Neck Cancer
11%
Head and Neck Squamous Cell Carcinoma
11%
Human Papillomavirus
9%
Human Papillomavirus Type 16
7%
Immunotherapy
6%
Irinotecan
9%
Malignant Neoplasm
26%
Mouse
7%
Neoplasm
67%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
7%
Nivolumab
7%
Non Small Cell Lung Cancer
7%
Overall Survival
40%
Paclitaxel
6%
Pancreas Adenocarcinoma
21%
Pancreas Cancer
17%
Pharmacodynamics
7%
Phase II Trials
11%
Placebo
7%
Programmed Death 1 Ligand 1
7%
Progression Free Survival
30%
Prostate Cancer
62%
Prostate Specific Antigen
35%
Radiopharmaceutical Agent
6%
Recurrent Disease
5%
Tumor Growth
7%
Vaccination Policy
7%
Keyphrases
Abiraterone
25%
Androgen Deprivation Therapy
21%
Anti-PD-1 Therapy
8%
Bipolar Androgen Therapy
24%
Castration-resistant Prostate Cancer
11%
Chemoradiation
9%
Clinical Outcomes
11%
Colon Cancer
7%
Colorectal Cancer
23%
Confidence Interval
13%
Docetaxel
7%
Enzalutamide
34%
Germ Cells
8%
Hazard Ratio
10%
Head-and-neck Cancer
10%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
16%
High Risk
16%
High-risk Human Papillomavirus (HR-HPV)
7%
Localized Prostate Cancer
8%
Median Overall Survival
9%
Metastasis
8%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
39%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
19%
Metastatic Pancreatic Ductal Adenocarcinoma
9%
Mismatch Repair
20%
Neoadjuvant
12%
Neoadjuvant Therapy
8%
Nivolumab
18%
Oligometastatic Prostate Cancer
10%
Overall Survival
37%
Pancreatic Adenocarcinoma
18%
Pancreatic Cancer
9%
Pancreatic Ductal Adenocarcinoma
18%
Pathologic
9%
PD-1 Blockade
8%
Phase II Study
13%
Phase II Trial
17%
Positron Emission Tomography-computed Tomography (PET-CT)
7%
Programmed Death-ligand 1 (PD-L1)
19%
Progression-free Survival
19%
Prostate Cancer
13%
Prostate-specific Antigen
19%
Radical Prostatectomy
11%
Recurrent Prostate Cancer
14%
Response Predictors
10%
Response Rate
8%
Stereotactic Ablative Radiotherapy
10%
Tumor
35%
Tumor Cells
8%
Tumor Microenvironment
8%